Market Cap 572.61M
Revenue (ttm) 332.31M
Net Income (ttm) -51.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 232.50
Profit Margin -15.57%
Debt to Equity Ratio -0.34
Volume 4,550,500
Avg Vol 5,635,480
Day's Range N/A - N/A
Shares Out 201.62M
Stochastic %K 93%
Beta 0.89
Analysts Sell
Price Target $5.80

Company Profile

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovasc...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 734 887 3903
Address:
3891 Ranchero Drive, Suite 150, Ann Arbor, United States
fedeblu
fedeblu Sep. 14 at 6:41 PM
$ESPR could be the Japanese approval a buy on rumors and sell on news risk for us?
1 · Reply
CoopersHawk
CoopersHawk Sep. 14 at 4:22 PM
$ESPR Researching the timeline for a leading indicator of when exactly we can expect Japan approval One way to gauge if the Minister’s sign-off is close is to watch the scheduled meetings of the Pharmaceutical Affairs Council, which is the higher-level council that formally advises the Minister after the expert committees. According to MHLW’s schedule, the Pharmaceutical Affairs Council is set to convene a meeting on September 16, 2025 – roughly 2½ weeks after the Aug 29 committee recommendation. There is no fixed statutory lag afterward. If MHLW follows the usual late-September batching pattern, expect potential postings on the meeting day or within ~0–3 business day. Also keep in mind Japanese government holidays September 15th and 23rd.
1 · Reply
BullDonald
BullDonald Sep. 14 at 4:18 PM
0 · Reply
Stock765
Stock765 Sep. 14 at 3:53 PM
$ESPR BIG IN JAPAN https://youtu.be/HcsYb3OoM8c?si=-w0a3NjXELCSAcB1
0 · Reply
RayDelauney
RayDelauney Sep. 14 at 3:50 PM
$ESPR ok, lets see who gets it right :) Predictions on the 1. The testing outcome and 2. Share price shift following news. I’ll start with a cautious view (still bullish on long term) 1. Narrow approval due to less impressive results. 2. Up 10-12% on the day (that it is ratified). I hope I’m wrong and it’s better news and goes higher.
1 · Reply
Midengine2021
Midengine2021 Sep. 14 at 3:47 PM
0 · Reply
Albertowest
Albertowest Sep. 14 at 3:41 PM
$ESPR fuck me, options expire same day 😂
1 · Reply
msp12389
msp12389 Sep. 14 at 3:31 PM
$ESPR Tuesday 9/16 MHLW meeting. https://www.mhlw.go.jp/stf/newpage_62638.html Nexletol is item 5 on the agenda. https://www.mhlw.go.jp/content/11121000/001551720.pdf Use browser's translate function.
0 · Reply
stormyfish
stormyfish Sep. 14 at 3:03 PM
$ESPR $10+ I am going to buy myself some grillz. https://www.youtube.com/watch?v=8fijggq5R6w&start_radio=1
1 · Reply
BBRC
BBRC Sep. 14 at 2:24 PM
$ESPR What you say is true. In practicality, it is done after PMDA. PMDA approves it, and the Ministry of Health signs the letter.
1 · Reply
Latest News on ESPR
Top 2 Health Care Stocks That May Plunge This Month

Sep 5, 2025, 10:39 AM EDT - 9 days ago

Top 2 Health Care Stocks That May Plunge This Month

NUVB


Esperion Appoints Craig Thompson to Board of Directors

Jul 1, 2025, 8:06 AM EDT - 2 months ago

Esperion Appoints Craig Thompson to Board of Directors


Esperion to Participate in The Citizens Life Sciences Conference

Apr 25, 2025, 8:00 AM EDT - 5 months ago

Esperion to Participate in The Citizens Life Sciences Conference


Esperion Appoints Robert E. Hoffman to Board of Directors

Apr 1, 2025, 8:00 AM EDT - 5 months ago

Esperion Appoints Robert E. Hoffman to Board of Directors


Esperion Announces $210 Million Convertible Debt Financing

Dec 13, 2024, 6:00 AM EST - 9 months ago

Esperion Announces $210 Million Convertible Debt Financing


Will The Long Awaited Breakout For Esperion Therapeutics Hold?

Dec 8, 2024, 7:43 AM EST - 10 months ago

Will The Long Awaited Breakout For Esperion Therapeutics Hold?


Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy

Nov 13, 2024, 2:08 AM EST - 10 months ago

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy


Esperion Therapeutics: Strategically Positioned To Grow

Aug 16, 2024, 4:09 AM EDT - 1 year ago

Esperion Therapeutics: Strategically Positioned To Grow


Esperion to Participate in Upcoming June Investor Conferences

May 23, 2024, 9:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming June Investor Conferences


Esperion Reports First Quarter 2024 Financial Results

May 7, 2024, 6:00 AM EDT - 1 year ago

Esperion Reports First Quarter 2024 Financial Results


Esperion to Participate in Upcoming May Investor Conferences

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Esperion to Participate in Upcoming May Investor Conferences


fedeblu
fedeblu Sep. 14 at 6:41 PM
$ESPR could be the Japanese approval a buy on rumors and sell on news risk for us?
1 · Reply
CoopersHawk
CoopersHawk Sep. 14 at 4:22 PM
$ESPR Researching the timeline for a leading indicator of when exactly we can expect Japan approval One way to gauge if the Minister’s sign-off is close is to watch the scheduled meetings of the Pharmaceutical Affairs Council, which is the higher-level council that formally advises the Minister after the expert committees. According to MHLW’s schedule, the Pharmaceutical Affairs Council is set to convene a meeting on September 16, 2025 – roughly 2½ weeks after the Aug 29 committee recommendation. There is no fixed statutory lag afterward. If MHLW follows the usual late-September batching pattern, expect potential postings on the meeting day or within ~0–3 business day. Also keep in mind Japanese government holidays September 15th and 23rd.
1 · Reply
BullDonald
BullDonald Sep. 14 at 4:18 PM
0 · Reply
Stock765
Stock765 Sep. 14 at 3:53 PM
$ESPR BIG IN JAPAN https://youtu.be/HcsYb3OoM8c?si=-w0a3NjXELCSAcB1
0 · Reply
RayDelauney
RayDelauney Sep. 14 at 3:50 PM
$ESPR ok, lets see who gets it right :) Predictions on the 1. The testing outcome and 2. Share price shift following news. I’ll start with a cautious view (still bullish on long term) 1. Narrow approval due to less impressive results. 2. Up 10-12% on the day (that it is ratified). I hope I’m wrong and it’s better news and goes higher.
1 · Reply
Midengine2021
Midengine2021 Sep. 14 at 3:47 PM
0 · Reply
Albertowest
Albertowest Sep. 14 at 3:41 PM
$ESPR fuck me, options expire same day 😂
1 · Reply
msp12389
msp12389 Sep. 14 at 3:31 PM
$ESPR Tuesday 9/16 MHLW meeting. https://www.mhlw.go.jp/stf/newpage_62638.html Nexletol is item 5 on the agenda. https://www.mhlw.go.jp/content/11121000/001551720.pdf Use browser's translate function.
0 · Reply
stormyfish
stormyfish Sep. 14 at 3:03 PM
$ESPR $10+ I am going to buy myself some grillz. https://www.youtube.com/watch?v=8fijggq5R6w&start_radio=1
1 · Reply
BBRC
BBRC Sep. 14 at 2:24 PM
$ESPR What you say is true. In practicality, it is done after PMDA. PMDA approves it, and the Ministry of Health signs the letter.
1 · Reply
CoopersHawk
CoopersHawk Sep. 14 at 2:16 PM
$ESPR It's my impression PMDA (Pharmaceuticals and Medical Devices Agency) recommends approval. It produces a review report that is submitted internally to the MHLW (Ministry of Health, Labour and Welfare). The MHLW makes the final approval decision and publishes it on its website. This is the formal approval (marketing authorization). Looking at the last 5 years (history) of timelines for late September PMDA meetings the formal approval (MHLW) has come within 3-5 weeks. So if were early approval could come by end of the week and base case in end of next week.
2 · Reply
Gregg617
Gregg617 Sep. 14 at 5:50 AM
$ESPR $ESPR — I have been thinking it’s time to dive into PERFORMANCE. Too often the focus stays on red/green days or single candles, but for me, technicals are the story of human behavior printed on the charts. On the monthly view, price is now above the 23EMA and inside the Ichimoku cloud with the 50MA near $3.75, signaling the first phase of a long-term uptrend is underway. The weekly performance is also strong, trading above the Ichimoku and on the verge of a 23EMA and 50MA crossover, which confirms continuation. On the daily chart momentum is in full motion, the daily led first, the weekly is following, and the monthly is finally aligning. This multi-timeframe strength is what drives sustainable moves, and it’s the reason I believe ESPR is just beginning its next phase. I truly appreciate the push from all of you because it challenges me to become a sharper technical investor, and I hope this perspective gives more clarity to ESPR’s direction. To The Moon &am🫡 🌖
7 · Reply
Gary9912
Gary9912 Sep. 14 at 3:05 AM
$ESPR 👀👀👀🍿🍿🍿
1 · Reply
Heliosphere
Heliosphere Sep. 14 at 1:19 AM
$ESPR Can options be extended under certain circumstances?
0 · Reply
omar_progressivetrading
omar_progressivetrading Sep. 13 at 11:53 PM
$ESPR — Time to dive into PERFORMANCE. Too often the focus stays on red/green days or single candles, but for me, technicals are the story of human behavior printed on the charts. On the monthly view, price is now above the 23EMA and inside the Ichimoku cloud with the 50MA near $3.75, signaling the first phase of a long-term uptrend is underway. The weekly performance is also strong, trading above the Ichimoku and on the verge of a 23EMA and 50MA crossover, which confirms continuation. On the daily chart momentum is in full motion, the daily led first, the weekly is following, and the monthly is finally aligning. This multi-timeframe strength is what drives sustainable moves, and it’s the reason I believe ESPR is just beginning its next phase. I truly appreciate the push from all of you because it challenges me to become a sharper technical investor, and I hope this perspective gives more clarity to ESPR’s direction. To The Moon & Beyond! 🫡 🌖
0 · Reply
Lskynrd1
Lskynrd1 Sep. 13 at 11:38 PM
$ESPR So are we going to get a surprise bounce next week for Foody, has to be Mon or Tues right. Going to the wire🤞
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Sep. 13 at 10:59 PM
Enter: $ESPR OCT 17 2025 $3 CALLS Buy in Price: $0.30 - $0.35 Take Profit: $0.36 Stop Bleeding: $0.26 ROI Potential: 20% Exit Within: 49 Minutes https://moneygroup.us/alerts
0 · Reply
Enjoyycall
Enjoyycall Sep. 13 at 10:18 PM
$ESPR Another good week in the books. You can almost smell who sold on Friday. This is not the same stock ladies and gentlemen. 🆙🆙 and away!
0 · Reply
PKinUK16
PKinUK16 Sep. 13 at 9:12 PM
$ESPR @djohnson591 amen brother…one day
0 · Reply
If_
If_ Sep. 13 at 9:05 PM
$ESPR still here, still enjoying the ride. I think the coming weeks and months will be great for the longs and I appreciate all the great DD which is shared on this board.
0 · Reply
profitsforall
profitsforall Sep. 13 at 8:02 PM
$ESPR @travis302185 is a COMPLETE MORON....BLOCK
1 · Reply
djohnson591
djohnson591 Sep. 13 at 7:59 PM
$ESPR For those that have been on this board for several years, we can all see right through the bullshit. Spread as much FUD as you want assholes, I'm not selling on share until a BO occurs and I'll just load more on every dip. The winds have changed and I'm riding them all the way to the Bahamas.
1 · Reply